Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • Effectiveness and safety of pr...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
Effectiveness and safety of proprotein convertase subtilisin/kexin type 9 inhibitors in patients with familial hypercholesterolemia. Our experience in implementing the drug program of the Polish National Health Fund

Effectiveness and safety of proprotein convertase subtilisin/kexin type 9 inhibitors in patients with familial hypercholesterolemia. Our experience in implementing the drug program of the Polish National Health Fund

Bibliographic Details
Main Authors: Beata Bobrowska, Agata Krawczyk-Ożóg, Stanisław Bartuś, Renata Rajtar-Salwa
Format: Article
Language:English
Published: Termedia Publishing House 2022-08-01
Series:Advances in Interventional Cardiology
Subjects:
proprotein convertase subtilisin/kexin type 9 inhibitors
alirocumab
evolocumab
heterozygous familial hypercholesterolemia
Online Access:https://www.termedia.pl/Effectiveness-and-safety-of-proprotein-convertase-subtilisin-kexin-type-9-inhibitors-in-patients-with-familial-hypercholesterolemia-Our-experience-in-implementing-the-drug-program-of-the-Polish-Nation,35,47586,1,1.html
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

https://www.termedia.pl/Effectiveness-and-safety-of-proprotein-convertase-subtilisin-kexin-type-9-inhibitors-in-patients-with-familial-hypercholesterolemia-Our-experience-in-implementing-the-drug-program-of-the-Polish-Nation,35,47586,1,1.html

Similar Items

  • Efficacy of Alirocumab, Evolocumab, and Inclisiran in Patients with Hypercholesterolemia at Increased Cardiovascular Risk
    by: Renata Rajtar-Salwa, et al.
    Published: (2024-07-01)
  • New groups of hypolipidemic drugs based on inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9). Part 1
    by: Aleksey M. Chaulin, et al.
    Published: (2021-03-01)
  • The role of proprotein convertase subtilisin/kexin type 9 inhibitors in managing cardiovascular risk
    by: Natalie Schellack, et al.
    Published: (2016-01-01)
  • Clinical studies of monoclonal antibodies against the proprotein convertase subtilisin / kexin type 9
    by: K. S. Astrakova, et al.
    Published: (2015-06-01)
  • Phenotypic homozygous familial hypercholesterolemia successfully treated with proprotein convertase subtilisin/kexin type 9 inhibitors
    by: Ryosuke Tani, et al.
    Published: (2024-02-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs